Literature DB >> 30069030

Follow-up of differentiated thyroid cancer - what should (and what should not) be done.

Livia Lamartina1, Giorgio Grani1, Cosimo Durante1, Isabelle Borget2, Sebastiano Filetti1, Martin Schlumberger3.   

Abstract

The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to more personalized protocols that range from active surveillance to total thyroidectomy followed by radioiodine remnant ablation. Accurate surveillance tools are available, but follow-up protocols vary widely between centres and clinicians, owing to the lack of clear, straightforward recommendations on the instruments and assessment schedule that health-care professionals should adopt. For most patients (that is, those who have had an excellent response to the initial treatment and have a low or intermediate risk of tumour recurrence), an infrequent assessment schedule is sufficient (such as a yearly determination of serum levels of TSH and thyroglobulin). Select patients will benefit from second-line imaging and more frequent assessments. This Review discusses the strengths and weaknesses of the surveillance tools and follow-up strategies that clinicians use as a function of the initial treatment and each patient's risk of recurrence.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30069030     DOI: 10.1038/s41574-018-0068-3

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  21 in total

1.  Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?

Authors:  Tian Tian; Rui Huang; Bin Liu
Journal:  Endocrine       Date:  2019-03-28       Impact factor: 3.633

2.  SEOM clinical guideline thyroid cancer (2019).

Authors:  E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila
Journal:  Clin Transl Oncol       Date:  2020-01-31       Impact factor: 3.405

3.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

4.  Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.

Authors:  G Grani; D Tumino; V Ramundo; L Ciotti; C Lomonaco; M Armillotta; R Falcone; P Lucia; M Maranghi; S Filetti; C Durante
Journal:  J Endocrinol Invest       Date:  2019-06-15       Impact factor: 4.256

5.  Ultrasonography surveillance in papillary thyroid carcinoma patients after total thyroidectomy according to dynamic risk stratification.

Authors:  Jiyoung Yoon; Jung Hyun Yoon; Kyunghwa Han; Jandee Lee; Eun-Kyung Kim; Hee Jung Moon; Vivian Youngjean Park; Jin Young Kwak
Journal:  Endocrine       Date:  2020-05-24       Impact factor: 3.633

6.  Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue.

Authors:  Antonella Verrienti; Valeria Pecce; Luana Abballe; Valeria Ramundo; Rosa Falcone; Farzaneh Inanloo Nigi Jak; Chiara Brunelli; Guido Fadda; Daniela Bosco; Valeria Ascoli; Raffaella Carletti; Cira Di Gioia; Giorgio Grani; Marialuisa Sponziello
Journal:  Endocrine       Date:  2020-06-06       Impact factor: 3.633

Review 7.  Current practice in patients with differentiated thyroid cancer.

Authors:  Martin Schlumberger; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2020-12-18       Impact factor: 43.330

8.  Long-Term Outcome of Lobectomy for Thyroid Cancer.

Authors:  Matthieu Bosset; Maxime Bonjour; Solène Castellnou; Zakia Hafdi-Nejjari; Claire Bournaud-Salinas; Myriam Decaussin-Petrucci; Jean Christophe Lifante; Agnès Perrin; Jean-Louis Peix; Philippe Moulin; Geneviève Sassolas; Michel Pugeat; Françoise Borson-Chazot
Journal:  Eur Thyroid J       Date:  2020-09-29

9.  LncRNAs as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Zeeshan Javed; Faiez Ahmed Shah; Sadegh Rajabi; Qamar Raza; Zaheer Iqbal; Mukhtar Ullah; Touqeer Ahmad; Bahare Salehi; Mehdi Sharifi-Rad; Raffaele Pezzani; Farooq Yaqoob; Haleema Sadia; Marcello Iriti; Javad Sharifi-Rad; William C Cho
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

10.  Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies.

Authors:  Rosa Falcone; Giorgio Grani; Valeria Ramundo; Rossella Melcarne; Laura Giacomelli; Sebastiano Filetti; Cosimo Durante
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.